Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Влияние генетических факторов на концентрацию клопидогреля в плазме крови у больных с сердечно-сосудистой патологией

E-mail: Сведения доступны для зарегистрированных пользователей.

Link: Clinical Physiology of Blood Circulaiton. 2010; (): -

Download
Full text:  

Abstract

The work objective was the study of CYP2C19, MDR1 and P2Y12 polymorphism genes influence on concentration of active metabolite clopidogrelum in patients blood plasma with cardiovascular pathology. 26 patients with ischemic disease and ischemic stroke were evaluated. Genotypes on the points of polymorphism were determined by the method of minisequencing with the following MALDI-TOF mass-spectrometry. The concentration of clopidogrelum metabolite in plasma was measured using chromatography- mass-spectometric quantitative analysis. The association of functional defective alleles 2* and 3* of CYP2C19 gene with the concentration of active metabolite clopidogrelum in plasma was revealed. The concentration was lower in patient with 1*/2* and 1*/3* genotypes in comparison with patients with 1*/1* (0,23±0,09 vs 1,12±0,93; p=0,013 for CYP2C19*2 and 0,27±0,16 vs 1,10±0,94; p=0,014 for CYP2C19*3). There was no significant relation between polymorphous markers C3435T gene MDR1 and T744C gene P2Y12, and the concentration of clopidogrelum in plasma. Thus, allelic variants of CYP2C19 gene can be involved in the development of resistance to clopidogrelum.

References

1. Кукес, В. Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты / В. Г. Кукес. - М.: Реафарм, 2004.
2. Fontana, P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects / P. Fontana, A. Dupont, S. Gandrille et al. // Circulation. - 2003. - Vol. 108. - P. 989-995.
3. Ford, N. F. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? / N. F. Ford // J. Clin. Pharmacol. - 2009. - Vol. 49, № 5. - P. 506-512.
4. Freedman, J. E. Clopidogrel, genetics and drug responsiveness / J. E. Freedman, E. M. Hylek // N. Engl. J. Med. - 2009. - Vol. 360, № 4. - P. 411-413.
5. Giusti, B. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients / B. Giusti, A. M. Gori, R. Marcucci et al. // Pharmacogenet. Genomics. - 2007. - Vol. 17, № 12. - P. 1057-1064.
6. Hulot, J. S. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects / J. S. Hulot, A. Bura, E. Villard et al. // Blood. - 2006. - Vol. 108. - P. 2244-2247.
7. Kim, K. A. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance / K. A. Kim, P. W. Park, S. J. Hong et al. // Clin. Pharmacol. Ther. - 2008. - Vol. 84. - P. 236-242.
8. Mega, J. L. Cytochrome P-450 polymorphisms and response to clopidogrel / J. L. Mega, S. L. Close, S. D. Wiviott et al. // N. Engl. J. Med. - 2009. - Vol. 360. - P. 354-362.
9. Schettert, I. T. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease / I. T. Schettert, A. C. Pereira, N. H. Lopes et al. // Thrombosis Research. - 2006. - Vol. 118. - P. 679-683.
10. Simon, T. Genetic determinants of response to clopidogrel and cardiovascular response / T. Simon, S. Verstuyft, M. Mary- Crause et al. // N. Engl. J. Med. - 2009. - Vol. 360. - P. 363-375.
11. Takahashi, M. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS / M. Takahashi, H. Pang, K. Kawabata et al. // J. Pharmaceutic. Biomed. Analys. - 2008. - Vol. 48, № 4. - P. 1219-1224.
12. Taubert, D. Impact of P-glycoprotein on clopidogrel absorbtion / D. Taubert, N. von Beckerath, G. Grimberg et al. // Clin. Pharmacol. Ther. - 2006. - Vol. 80, № 5. - P. 486-501.

 If you found mistakes, select text and press Alt+A